| 多肽新药研发策略研究进展 |
| |
| 引用本文： | 张伟,宋竟婧,张邦治,杨雯乐,王锐. 多肽新药研发策略研究进展[J]. 中国科学B辑, 2013, 0(8): 941-952 |
| |
| 作者姓名： | 张伟 宋竟婧 张邦治 杨雯乐 王锐 |
| |
| 作者单位： | 甘肃省新药临床前研究省重点实验室,兰州大学基础医学院生物化学与分子生物学研究所,兰州730000 |
| |
| 基金项目： | 国家自然科学基金项目（91213302,20932003,21272102）; “重大新药创制”科技重大专项（2012ZX09504001-003）; 长江学者和创新团队发展计划（IRT1137）的资助.本工作得到国家自然科学基金项目（91213302,20932003,21272102）、“重大新药创制”科技重大专项（2012ZX09504001.003）以及长江学者和创新团队发展计划（IRTll37）的资助,特此一并致谢. |
| |
| 摘 要： | 多肽药物具有生物活性高、药用剂量小、产业化开发优势明显等诸多优点,已成为全球关注的创新药物研发热点之一.但是其代谢不稳定、半衰期短及较难通透组织屏障等缺点严重阻碍了多肽新药在临床治疗中的广泛应用.为了解决这些限制多肽药物的瓶颈,本课题组发展了一系列的改造策略.通过这些策略的应用,以期加快多肽药物临床应用的步伐.本文主要结合本课题组的工作对多肽新药创制过程中所遇到的关键问题及解决思路进行综述.
|
| 关 键 词： | 多肽药物 神经肽 抗菌肽 靶向肽 穿膜肽 |
Advances in the strategies for the development of novel peptide drugs |
| |
| ZHANG Wei,SONG JingJing,ZHANG BangZhi,YANG WenLe,WANG Rui. Advances in the strategies for the development of novel peptide drugs[J]. Science in China(Series B), 2013, 0(8): 941-952 |
| |
| Authors: | ZHANG Wei SONG JingJing ZHANG BangZhi YANG WenLe WANG Rui |
| |
| Affiliation: | ＊Key Laboratory of Preclinical Study for New Drugs of Gansu Province; Institute of Biochemistry and Molecular Biology,School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China |
| |
| Abstract: | The development of peptide drugs has become a global concern due to their merits such as high biological activity, low medicinal dose and easy to industrialization. However, low enzymatic stability, short half-life and low tissue permeability hamper the clinical application of nature peptide drugs. In order to overcome the bottlenecks, we developed a series of new modified strategies. By applications of these strategies, we wish to accelerate the pace of the development in clinical application of peptide drugs. |
| |
| Keywords: | peptide drug neuropeptide antimicrobial peptide targeting peptide cell penetrating peptide |
| 本文献已被 维普 等数据库收录！ |
|
